DUBLIN--(BUSINESS WIRE)--The "Global Glaucoma treatment Market Research and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.
The global glaucoma treatment market is emerging with a rapid speed due to some of the major factors such as growing incidences of glaucoma diseases across the globe.
Increasing old age population in various regions has become one of the reasons for the growth of this market. Various initiatives by the government and healthcare institutions in order to cure glaucoma related problems have helped for the growth of this segment. The market is also driven by favourable reimbursement policies related to glaucoma treatment.
The continuous innovations in drugs and rising number of patients with diabetes have resulted in significant growth opportunities. Although there are some factors which hinders the growth of market. This comprise of lack of awareness about the disease and its treatment in various developing and underdeveloped regions, and postoperative complications resulting after glaucoma surgery.
The global glaucoma treatment market is studied on the basis of these segments: products, disease indication, end user and drug class.
Based on the product, the market is further subdivided as glaucoma drainage devices, implants and stents and glaucoma laser devices.
On the basis of disease indication, the market is sub-segmented as closed angle glaucoma, open angle glaucoma, congenital glaucoma and secondary glaucoma.
Furthermore, according to the end user, the market is bifurcated as hospitals, eye care clinics and home care.
According to the drug class, the market is diversified as prostaglandin analogues, alpha agonist, cholinergic, beta blockers and carbonic anhydrase inhibitors.
1. Report Summary
2. Market Overview & Insights
3. Market Determinant
4. Market Segmentation
5. Competitive Landscape
6. Regional Analysis
7. Company Profiles
- Bausch & Lomb Incorporation
- F. Hoffmann-La Roche
- Hoya Corporation
- Inotek Pharmaceuticals Corporation
- Johnson & Johnson
- Merck & Co.
- Teva Pharmaceuticals Industries
- Topcon Corporation
- Valeant Pharmaceuticals International
For more information about this report visit https://www.researchandmarkets.com/research/zd5wlg/global_glaucoma?w=4